Simparica Trio™ Now Licenced To Treat Lungworm
4 months ago 
3542 views
Zoetis UK Ltd today announced that Simparica Trio™ is now licensed for the treatment of Angiostrongylus vasorum in dogs. It makes Simparica Trio™ the only oral moxidectin that is licensed to treat A.vasorum in dogs in the UK.
“The last time a product was licensed for the treatment of lungworm in the UK was some time ago, so this is an especially important development,” Louise Longstaff, National Veterinary Manager at Zoetis UK. “Simparica Trio™ offers a new licensed route of administration for lungworm treatment in dogs, giving vets another option to that which is currently available. It enables them to tailor treatment based on their patient’s needs while still prescribing within the cascade.”
Simparica Trio™ is a chewable tablet for dogs containing sarolaner, moxidectin and pyrantel. It is a monthly tablet that kills fleas and ticks, treats mites, roundworm and hookworm, prevents and treats lungworm and prevents heartworm disease.1
Louise continued: “Zoetis has a strong history of research, innovation and development. This new claim for Simparica Trio™ ably demonstrates our commitment to delivering a diverse portfolio of animal health medicines, designed to meet the continually evolving needs of veterinarians, giving them best in class products to help support companion animals and their owners.”
For further information contact your Zoetis Account Manager or call Customer Support on 0345 300 8034.
Reference
1Simparica™ Trio SPC
More from Zoetis
- Zoetis Hosts Free Webinar to Share Latest Knowledge of Lungworm
- Vets Urge Action as Dog Arthritis Misconceptions Persist
- Zoetis Acquires Veterinary Pathology Group to Strengthen Veterinary Diagnostics in UK and Ireland
- Zoetis to Unveil End-to-End Support for Veterinary Care at London Vet Show 2025
- Vets asked to circulate clostridial disease survey to their farming clients
4 weeks ago